LRRK2 and Parkinson disease: While there has been a lot of promising work in the development of LRRK2 kinase inhibitors for a novel disease-modifying therapy, determining the mechanistic changes to LRRK2 due to PD-associated mutation will help to define the cellular processes affected by these treatments.